标题:Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
作者:Zhang, Di; Huang, Jiaqi; Sun, Yulan; Guo, Qisen
作者机构:[Zhang, Di; Huang, Jiaqi; Guo, Qisen] Shandong Univ, Shandong Canc Hosp, Jinan 250117, Shandong, Peoples R China.; [Zhang, Di; Huang, Jiaqi; Sun, Yu 更多
通讯作者:Guo, QS
通讯作者地址:[Guo, QS]Shandong Univ, Shandong Canc Hosp, Shandong Canc Hosp & Inst, Shandong Acad Med Sci, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.
来源:ONCOTARGETS AND THERAPY
出版年:2019
卷:12
页码:3635-3644
DOI:10.2147/OTT.S198946
关键词:ovarian cancer; apatinib monotherapy; anti-angiogenic therapy; vascular; endothelial growth factor receptor
摘要:Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable therapeutic effect in a wide variety of tumors. We report a woman with advanced ovarian cancer who received apatinib at 250 mg/day after failure of multiple-line treatment regimens, followed by discussion through review of literature. The patient has quite a long progression-free survival time of 24 months, with a satisfactory quality of life. Apatinib monotherapy may provide an additional option for advanced ovarian cancer, but it still needs further observation and exploration.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067497269&doi=10.2147%2fOTT.S198946&partnerID=40&md5=f7face37f763e02a4419491711930c81
TOP